% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Zeyen:1018548,
      author       = {Zeyen, Thomas and Paech, Daniel and Weller, Johannes and
                      Schäfer, Niklas and Tzaridis, Theophilos and Duffy,
                      Cathrina and Nitsch, Louisa and Schneider, Matthias and
                      Potthoff, Anna-Laura and Steinbach, Joachim Peter and Hau,
                      Peter and Schlegel, Uwe and Seidel, Clemens and Krex,
                      Dietmar and Grauer, Oliver and Goldbrunner, Roland and
                      Zeiner, Pia Susan and Tabatabai, Ghazaleh and Galldiks,
                      Norbert and Stummer, Walter and Hattingen, Elke and Glas,
                      Martin and Radbruch, Alexander and Herrlinger, Ulrich and
                      Schaub, Christina},
      title        = {{U}ndetected pseudoprogressions in the {C}e{T}e{G}/{NOA}-09
                      trial: hints from postprogression survival and {MRI}
                      analyses},
      journal      = {Journal of neuro-oncology},
      volume       = {164},
      number       = {3},
      issn         = {0167-594X},
      address      = {Dordrecht [u.a.]},
      publisher    = {Springer Science + Business Media B.V},
      reportid     = {FZJ-2023-04876},
      pages        = {607 - 616},
      year         = {2023},
      note         = {Erratum in Correction to: Undetected pseudoprogressions in
                      the CeTeG/NOA-09 trial: hints from postprogression survival
                      and MRI analyses. Zeyen T, Paech D, Weller J, Schäfer N,
                      Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL,
                      Steinbach JP, Hau P, Schlegel U, Seidel C, Krex D, Grauer O,
                      Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer
                      W, Hattingen E, Glas M, Radbruch A, Herrlinger U, Schaub C.
                      J Neurooncol. 2023 Nov 3. doi: 10.1007/s11060-023-04488-z.},
      abstract     = {Purpose: In the randomized CeTeG/NOA-09 trial,
                      lomustine/temozolomide (CCNU/TMZ) was superior to TMZ
                      therapy regarding overall survival (OS) in MGMT
                      promotor-methylated glioblastoma. Progression-free survival
                      (PFS) and pseudoprogression rates (about $10\%)$ were
                      similar in both arms. Further evaluating this discrepancy,
                      we analyzed patterns of postprogression survival (PPS) and
                      MRI features at first progression according to modified RANO
                      criteria (mRANO).Methods: We classified the patients of the
                      CeTeG/NOA-09 trial according to long vs. short PPS employing
                      a cut-off of 18 months and compared baseline characteristics
                      and survival times. In patients with available MRIs and
                      confirmed progression, the increase in T1-enhancing, FLAIR
                      hyperintense lesion volume and the change in ADC mean value
                      of contrast-enhancing tumor upon progression were
                      determined.Results: Patients with long PPS in the CCNU/TMZ
                      arm had a particularly short PFS (5.6 months). PFS in this
                      subgroup was shorter than in the long PPS subgroup of the
                      TMZ arm (11.1 months, p = 0.01). At mRANO-defined
                      progression, patients of the CCNU/TMZ long PPS subgroup had
                      a significantly higher increase of mean ADC values (p =
                      0.015) and a tendency to a stronger volumetric increase in
                      T1-enhancement (p = 0.22) as compared to long PPS patients
                      of the TMZ arm.Conclusion: The combination of survival and
                      MRI analyses identified a subgroup of CCNU/TMZ-treated
                      patients with features that sets them apart from other
                      patients in the trial: short first PFS despite long PPS and
                      significant increase in mean ADC values upon mRANO-defined
                      progression. The observed pattern is compatible with the
                      features commonly observed in pseudoprogression suggesting
                      mRANO-undetected pseudoprogressions in the CCNU/TMZ arm of
                      CeTeG/NOA-09.Keywords: Glioblastoma; MGMT promotor
                      methylation; MRI; Progression; Pseudoprogression.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525) / DFG
                      project 491111487 - Open-Access-Publikationskosten / 2022 -
                      2024 / Forschungszentrum Jülich (OAPKFZJ) (491111487)},
      pid          = {G:(DE-HGF)POF4-5252 / G:(GEPRIS)491111487},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {37728779},
      UT           = {WOS:001068390300001},
      doi          = {10.1007/s11060-023-04444-x},
      url          = {https://juser.fz-juelich.de/record/1018548},
}